#China #Hong Kong #Ascletis #Obesity Treatment #ASC30

Ascletis Launches Phase III Trials for ASC30

Ascletis Pharma Inc., headquartered in Hong Kong, has announced the initiation of a significant global Phase III clinical program for its innovative oral small molecule GLP-1, known as ASC30. This promising treatment aims at managing chronic weight in individuals dealing with obesity or being overweight. The trials will enroll approximately 4,600 participants across the United States, Europe, and Canada. The company's endeavor coincides with encouraging preclinical results from non-human primate studies, particularly for an exciting first-in-class oral small molecule combination that involves GLP-1, GIP, and amylin hormones.

Overview of the Clinical Trials

The Phase III study consists of two pivotal multicenter, randomized, double-blind, placebo-controlled trials named AURORA-1 and AURORA-2. The AURORA-1 trial will focus on participants with obesity but without type 2 diabetes, while the AURORA-2 trial will include participants with both obesity and type 2 diabetes. Each trial spans a duration of 72 weeks and will explore the efficacy and safety of three different doses of ASC30: 20 mg, 40 mg, and 60 mg.

The ascending dose strategy is structured around titration phases of 12, 16, and 20 weeks, depending on participants' cohort assignments. Preliminary results from this ambitious Phase III program are anticipated in the third quarter of 2028, followed by an application for New Drug Application (NDA) submission to the FDA and a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA).

Positive Preclinical Findings

In the journey leading up to these trials, Ascletis reported notable preclinical data highlighting the efficacy of its fixed-dose combination therapy, which includes GLP-1 and GIP. The recently announced results indicated significant reductions in body weight among non-human primates after only seven days of treatment. Specifically, this combination yielded up to a 15.2% reduction in body weight, marking a substantial improvement over prior combinations. This positions Ascletis to potentially revolutionize the management of obesity through oral medications.

A Comprehensive Portfolio

Beyond ASC30, Ascletis is paving the way with a diversified portfolio targeting obesity and metabolic diseases. The company is emphasizing its lead offerings which include multiple oral small molecule therapies, notably the once-daily oral small molecule triple agonist, and a dual agonist fixed-dose combination that reflects its competitive edge in this therapeutic area.

Among these innovative products, the performance of the ASC30_48FDC — a dual agonist combination of ASC30 and ASC48 — illustrated significant promise, achieving a notable body weight reduction through a unique mechanism of action. This holistic approach may unlock new possibilities for individuals who struggle with metabolic disorders.

Financial Viability

On the operational side, Ascletis has assured stakeholders that it possesses adequate financial resources to sustain its research and administrative functions into 2029. This includes anticipated timelines for regulatory submissions for ASC30, reinforcing confidence in the company's trajectory within the pharmaceutical landscape.

Looking Ahead

Ascletis Pharma's recent developments underline its commitment to addressing obesity-related challenges with cutting-edge therapies. The combination of a favorable preclinical environment, a well-structured clinical trial plan, and a sound financial foundation signals a pivotal moment for the company as it aims to support countless individuals affected by obesity. The initiation of global Phase III trials signifies a crucial step in its trajectory towards crafting the future of obesity treatment with oral therapeutics. As further developments unfold, the hopes of many will rest on the successful advancement of ASC30 and its associated therapies, heralding a new era in metabolic health.